Table 3.

Maternal HIV Disease Progression–Classifying Events Occurring up to 2 Years After Delivery^a

Events	Triple ARV, No. (%) [cumulative]	AZT/sdNVP, No. (%) [cumulative]
All women	n = 384	n = 405
Death	2 (0.5) [2]	5 (1.2) [5]
WHO stage 4 disease	2 (0.5) [4]	7 (1.7) [11]
At least 1 CD4+ count of <200 cells/mm3	39 (10.2) [40]	68 (16.8) [71]
Started on ART (whether or not having reached >1 of the above endpoints)	39 (10.2) [55]	65 (16.1) [88]
Women with CD4+ count of ≥350 cells/mm3 at entry	n = 169	n = 181
Death	1 (0.6) [1]	0 (0.0) [0]
WHO stage 4 disease	0 (0.0) [1]	2 (1.1) [2]
WHO stage 3 disease	11 (6.5) [12]	15 (8.3) [15]
At least 1 CD4+ count of <350 cells/mm3	43 (25.4) [49]	62 (34.3) [65]
Started on ART (whether or not having reached one or more of the above endpoints)	7 (4.1) [49]	8 (4.4) [65]

Abbreviations: ART, antiretroviral therapy; AZT/sdNVP, zidovudine until delivery with single-dose nevirapine without postpartum prophylaxis; HIV-1, human immunodeficiency virus type 1; Triple ARV, zidovudine, lamivudine, and lopinavir/ritonavir during pregnancy and breastfeeding; WHO, World Health Organization.

^aOne woman could have >1 event.